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The  transcription  factor  NF-B  is  needed  for the induction  of inﬂammatory  responses  in  T-cells.  Whether
its  activation  by the antigen-receptor  and  CD28  is mediated  by the  same  or different  intracellular  signaling
pathways  has  been  unclear.  Here,  using  T-cells  from  various  knock-out  (Cd28−/−, adap−/−) and  knock-in
(i.e.  Cd28  Y-170F)  mice  in conjunction  with  transfected  Jurkat  T-cells,  we  show  that  the  TCR  and  CD28
use  distinct  pathways  to activate  NF-B  in T-cells.  Anti-CD28  ligation  alone activated  NF-B  in primary
and  Jurkat  T-cells  as  measured  by  NF-B  reporter  and  EMSA  assays.  Anti-CD28  also  activated  NF-B
normally  in  primary  T-cells  from  adap−/− mice,  while  anti-CD3  stimulation  required  the  adaptor  ADAP.
Over-expression  of  ADAP  or its  binding  partner  SKAP1  failed  to enhance  anti-CD28  activation  of  NF-B,
while  ADAP  greatly  increased  anti-CD3  induced  NF-B  activity.  By contrast,  CD28  activation  of NF-B
depended  on  GRB-2  binding  to CD28  as seen  in CD28  deﬁcient  Jurkat  T-cells  reconstituted  with  the  CD28
YMN-FM  mutant,  and  in  primary  T-cells  from  CD28  Y170F  mutant  knock-in  mice.  CD28  associated  with
GRB-2,  and  GRB-2  siRNA  impaired  CD28  NF-B  activation.  GRB-2  binding  partner  and  guanine  nucleotide
exchange  factor,  VAV1,  greatly  enhanced  anti-CD28  driven  activation  of  NF-B.  Further,  unlike  in  the  case
of anti-CD28,  NF-B  activation  by anti-CD3  and  its cooperation  with  ADAP  was  strictly  dependent  on  LAT
expression.  Overall,  we  provide  evidence  that CD28  and  the  TCR complex  regulate  NF-B  via  different
signaling  modules  of  GRB-2/VAV1  and  LAT/ADAP  pathways  respectively.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
T-cell activation is controlled by the engagement of the T-cell
eceptor (TCR) and an array of co-stimulatory and co-inhibitory
olecules that encounter binding partners during antigen presen-
ation [1–3]. CD28 is a co-receptor that is engaged by ligands CD80
nd CD86 on antigen presenting cells (APCs) [4,5]. The activation
rocess is accompanied by the clustering of CD28 in a manner that
egulates the localization of protein kinase C theta, a marker for the
ormation of central supramolecular activation complex (cSMAC)
6–8]. CD28 is required for productive T-cell responses and sur-
ival [5,9–12,60]. Engagement of TCR without co-stimulation can
ead to anergy, a state of hypo-responsiveness [13,14]. Further,
D28 regulates metabolism and the mRNA stability of multiple
ytokines including IL-2 [15]. CD28 deﬁcient mice show defects in
Abbreviations: CD, cluster of differentiation (e.g. CD28); TCR, T-cell receptor
TCR);  NF-B, nuclear factor B; IB, inhibitor of NF-B; PBL, peripheral blood
ymphocytes; SKAP1, Src-kinase associated phosphoprotein 1.
∗ Corresponding author. Tel.: +44 01223 765663; fax: +44 01223 764733.
E-mail address: yrt20@cam.ac.uk (Y.R. Thaker).
ttp://dx.doi.org/10.1016/j.imlet.2014.10.020
165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
proliferation, cytokine production and cell survival [16,17]. Muta-
tional analysis of IL-2 promoter has identiﬁed the NF-B binding
site on CD28 response element (CD28RE) [18] as well as other
sites that are responsive to stimulation by the TCR [19,20]. In
this context, the transcription factor NF-B is regulated by liga-
tion of both CD3 and CD28 and is essential for T-cell activation
[21,22].
T-cell activation is mediated by an array of protein kinases
and adaptor proteins, the latter integrating signals for activation
[1,25]. Adaptors lack enzymatic activity and transcription binding
domains, but facilitate protein-protein interactions [26]. The fam-
ily of adaptors in T-cells includes linker for activation of T-cells
(LAT), lymphocyte cytosolic protein-2 (SLP-76), adaptor adhesion
and degranulation promoting adaptor protein (ADAP or Fyb), VAV1
and SKAP1 [1,27,28]. Recently, role of adaptors have emerged in the
regulation of NF-B. ADAP can be recruited to the Carma1-Bcl10-
Malt1 (CBM) complex upon CD3/CD28 stimulation, a key complex
that regulates NF-B activation via the classical pathway [29,30].
Also, a role for the multi-domain adaptor VAV1 has been noted
in the CD28-NF-B  pathway [31]. VAV1 is a GTP exchange fac-
tor (GEF) protein for Rho/Rac family of GTPases required for the
optimal effector responses and cytoskeleton actin polymerization
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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32,33]. Unlike in the case of TCR and CD28, Toll receptors and IL-1
f innate signaling use the MyD88 adaptor-like, TRAF-6, and Rac1
or the activation of NF-B [23,24].
Despite the importance of CD28 in potentiating TCR activation of
-cells (i.e. co-stimulation), increasing evidence has shown that its
igation alone can induce signaling events in T-cells [31,34,35]. For
xample, mitogenic anti-CD28 can induce proliferation in absence
f TCR ligation [36]. Further, non-mitogenic anti-CD28 can regu-
ate NFAT transcription via VAV1/SLP-76 adaptors independently
f TCR ligation [34]. We  previously showed that GEF VAV1 binding
o CD28 involves the intermediate binding of another adaptor GRB-
 [37,38]. GRB-2 is a classic adaptor comprised of an SH2 domain
anked by an N- and C-terminal SH3 domain. Abe and coworkers
ave previously shown that the loss of either GRB-2 or GADS bind-
ng to CD28 can abrogate NK-B activation in Jurkat T-cells [39]. In
ddition, Tuosto et al. have reported that non-mitogenic anti-CD28
an deliver a unique signal leading to the recruitment of p52/Rel-A
omplexes on Bcl-xL promoter [40]. They showed that CD28 can
o-operate with VAV-1 to activate NF-B in a pathway involving
ac-1 and mitogen-activated kinase kinase 1 [31,41].
Despite this progress, studies dissecting the individual com-
onents of TCR and CD28-mediated NF-B activation in primary
-cells have been lacking. In this paper, using primary T-cells from
arious knock-out (Cd28−/−, adap−/−) and knock-in (i.e. Cd28 Y-
70F) mice in conjunction with transfected Jurkat T-cells, we show
hat the TCR and CD28 use distinct pathways for the activation of
he NF-B pathway in T-cells. Our ﬁndings provide further evidence
hat the CD28 and TCR pathways regulate NF-B activity via differ-
nt signaling modules of GRB-2/VAV1 and LAT/ADAP respectively.
. Materials and methods
.1. Mice and isolation of T-cells
DO11.10-CD28 KO and CD28 Y170F knock-in mutant mice
kindly provided by Dr. Jonathan Green, Washington University
chool of Medicine); C57BL/6-ADAP KO mice (kindly provided by
r. Erik Peterson, University of Minnesota, MN)  were bred and
oused under pathogen free conditions at the Central Biomedical
acility (CBS), University of Cambridge; Gurdon Institute, Animal
acility Unit, University of Cambridge; or Department of Pathol-
gy, Animal Unit (BSU), University of Cambridge. CD3+ cells were
nriched from splenocytes using a negative selection column kit
R&D Systems). Purity of isolated T-cells was greater than 90%.
.2. Cell culture and antibodies for ﬂow cytometry and activation
Mouse T-cells were cultured in RPMI 1640 supplemented
ith 10% fetal bovine serum (FBS, Sigma), 2 mM l-glutamine,
00 U/ml penicillin/streptomycin and 50 uM -mercapto-ethanol
t 37 degrees in 5% humidiﬁed chamber. Jurkat T-cells were
aintained in 5–10% FBS and 2 mM l-glutamine. Human anti-
D3 (OKT3) was obtained from American Type Culture Collection,
uman anti-CD28 (CD28.2 clone, BD Pharmingen), FITC labeled
nti-human CD28 (Cat. no. 556621, BD Pharmingen), anti-mouse
D3 antibody (2C11 clone, Bioexpress) and mouse anti-CD28 anti-
ody (PV-1 clone, Bioexpress).
.3. IL-2 NF-B minimal promoter activity
T-cells were transfected with IL-2 promoter binding sites NF-B
uciferase (ﬁreﬂy) reporter plasmid together with Renilla luciferase
lasmid (pRLTK, Promega) as an internal control to adjust for the
ransfection efﬁciency and background. Whenever described in
esults section cells were co-transfected with other effector plas-
ids in conjunction with empty vectors to adjust total amount oftters 163 (2015) 113–119
DNA. Following 24 h of expression, murine T-cells were treated
with anti-CD28 (PV1) or anti-CD3 (2C11) for 6 h. Jurkat T-cells
were stimulated with anti-CD28 (CD28.2) or anti-CD3 (OKT3) anti-
bodies and lysed in 100 l of passive lysis buffer provided with
dual luciferase assay kit (Promega). Light units were recorded on
Luminometer (Berthold) from 10 l of sample in 50 l substrate
solution as per the manufacturer’s instructions. Relative luciferase
units were derived by normalizing values relative to the Renilla
values. Each sample was measured in triplicates and ﬁnal average
values were plotted with standard deviations. Each experiment was
repeated at least three times.
2.4. Transfections of Jurkat and primary cells,
immunoprecipitation and blotting
Primary T-cells were transfected with 4 g of DNA per 8 million
cells using mouse or human Nucleofactor kit (Lonza). Brieﬂy, cells
were washed two times with PBS and resuspended in a mixture
of solution A and B (4.5:1 ratio) plus plasmid(s) and pulsed using
optimized protocol for CD4+ cells or human PBLs on Nucleofactor
2b device. Jurkat T-cells were transfected with 1–2 g of DNA per
1 million cells in RPMI without FBS and pulsed with a unipolar
pulse (310 V, 10 ms)  on BTX electroporator. Cells were immedi-
ately transferred to pre-equilibrated RPMI-1640 containing 10%
FBS and l-glutamine without antibiotics. Cells were lysed in NP-40
lysis buffer supplemented with protease inhibitor cocktail (Roche),
immunoprecipitated with 2 g of antibodies for 2 h at 4 degrees.
Immuno complexes were captured by protein G beads (GE Health-
care) and washed 4 times with lysis buffer and heated in loading
buffer. All samples were loaded onto 10% SDS gel (Novex, Invitro-
gen) and transferred onto PVDF membrane, followed by blotting
with primary and respective secondary antibodies.
2.5. Electromobility shift assay
CD3+ T-cells were stimulated with control or anti-CD28 antibod-
ies for 6 h at 37 degrees. Cells were harvested, lysed in hypotonic
buffer and nuclear fractions were isolated using nuclear extract kit
(ActiveMotif) as per the manufacturer’s instructions. Protein con-
centration was  quantiﬁed using BCA protein assay (Pierce). 4 g
of protein were used in each condition. A non-radioactive NF-B
electromobility shift assay (EMSA) was performed as per the man-
ufacturer’s instructions (Panomics, Afﬁmatrix) using biotinylated
NF-B probes and provided positive and negative controls.
2.6. siRNA knock-down
Control and gene-speciﬁc siRNA were purchased from Dhar-
macon (Thermo Scientiﬁc) and transfected into either primary or
Jurkat T-cells as described above. Cells were harvested for analysis
after 36 h or longer as described in the speciﬁc experiment.
3. Results
3.1. CD28 and TCR regulate and synergize the NF-B activation in
T-cells using independent and unique pathways
CD28 and TCR regulation of NF-B activation is well established
[40,42,43]. Whether CD28 and TCR use different pathways to reg-
ulate NF-B is not known. To assess this issue, anti-CD28 was
initially used in conjunction with anti-CD3 to examine effects on
NF-B activation. A reporter construct carrying the NF-B bind-
ing sites of the interleukin 2 promoter was  transfected into cells
and used as a readout [44,45]. Initially, 1G4 Jurkat T-cells deﬁcient
for CD28 expression were transfected with CD28 and ligated with
a non-mitogenic anti-CD28 and/or anti-CD3 antibodies (Fig. 1a).
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Fig. 1. CD28 and TCR uniquely regulated NF-B. (a) 1G4 CD28 deﬁcient Jurkat cells reconstituted with either empty plasmid (vector) or WT (CD28) untagged plasmid were
used  to measure NF-B IL-2 promoter luciferase (ﬁreﬂy) activity in response to indicated ligating antibodies. Activity was measured by normalizing ﬁreﬂy luciferase counts
to  the background Renilla luciferase values, done in triplicates for each point as described in Materials and Methods section. All values are in relative luciferase units. (b)
NF-B  activation in CD3+ human peripheral blood lymphocytes in response to engagement with indicated concentrations of CD3 (OKT3 clone) or CD28 (CD28.2 clone) alone
or  in combination. (c) Electromobility shift assay from nuclear fractions of C57BL/6 naïve T-cells as described in section 2. Brieﬂy, a biotinylated NF-B probe was used to
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nti-CD28 alone induced an increase in NF-B transcription on the
L-2 gene as reported [31,40]. Co-ligation of CD28 with CD3 co-
perated to produce higher transcription of luciferase gene (Fig. 1a).
imilar ﬁndings were observed in human peripheral T-cells trans-
ected with the NF-B reporter construct (Fig. 1b). Anti-CD28 alone
nduced an increase in NF-B promoter and cooperated with anti-
D3 ligation to further enhance NF-B activity. An electromobility
hift assay (EMSA) from nuclear extracts of anti-CD28 stimulated
rimary cells were probed with biotin-labeled NF-B probe and
howed signiﬁcant NF-B DNA binding (Fig. 1c). As a control, T-
ells from Cd28−/− mice showed a lack of NF-B activation by
nti-CD28. Despite this, anti-CD3 retained an ability to stimulate
F-B reporter activity (Fig. 1d). However, both anti-CD3 and CD28
riven pathways were normal in control animals. These data indi-
ated that anti-CD3 can activate NF-B transcription independently
f the expression of the CD28 on T-cells.
.2. CD28 requires GRB-2 binding to regulate NF-B activation
ndependent of TCR ligation
To dissect the nature of the CD28 proximal signaling pathway,
e initially made use of Jurkat cell lines, 1G4 and CH7C17, deﬁcient
or CD28 expression that were reconstituted by transfection with
ither WT  CD28 (WT), or a mutant form of CD28 (N193Q) (Fig. 2a).
ell clones stably expressing CD28 and N193 were selected and
sed for all subsequent experiments. FACS analysis showed equal
evels of CD28 and N193Q surface expression on the cells (inset). We
ad previously shown that the N193Q mutation selectively inter-
eres with GRB-2 binding, without affecting the binding of PI3K
42,46]. While anti-CD28 induced an increase reporter activity in
he CD28 reconstituted cells (i.e. 6- to 7-fold increase) (left handed cells (lane 2). For speciﬁcity, anti-CD28 stimulated nuclear fraction was  probed
d) NF-kB activation in primary T-cells isolated from WT or CD28 KO mice treated
n. Data in each sample is average of triplicates. All antibodies concentrations are in
panel), cells expressing the N193Q mutant showed an almost com-
plete impairment of NF-B activation, identical to the unstimulated
control. Similar results were obtained with CH7C17 Jurkat cell line
(right hand panel). Further, we  showed that primary cells from
CD28 knock-in mutant (Y170F), which disrupts binding of PI-3
kinase and GRB-2 to its YMNM motif also showed a complete loss
of NF-B activation by anti-CD28 (Fig. 2b).
A previous report had attributed this effect to a loss of either
GRB2 or GADS binding to CD28 [39]. To assess the relative binding
of each to CD28 in Jurkat cells, the co-receptor was ligated fol-
lowed by precipitation and blotting with either anti-GADS (Supp.
Fig. 1b and c) or anti-GRB2 (Fig. 2c). In agreement with our previ-
ous reports [37,46], GRB-2 was co-precipitated at substantive levels
over the time course of 1–30 min  by anti-CD28 (lanes 2–6). Binding
was also observed in resting cells (lane 2), and occasionally anti-
CD28 ligation resulted in an increased association (Supp. Fig. 1a,
lane 4). Blotting of cell lysates showed similar amounts of GRB-2
and CD28 (lower panel). By contrast, while similar amounts of GADS
and CD28 could be detected in the cell lysates (Supp. Fig. 1b and c),
anti-CD28 co-precipitated little or no GADS as compared to GRB-2
(Supp. Fig. 1b and c vs. Fig. 2c). In many experiments, GADS could
not be detected with anti-CD28 precipitates. This observation sug-
gested that GRB-2 was the adaptor primarily responsible for CD28
proximal complex assembly.
To establish this in primary and Jurkat T-cells, siRNA was used
to down-regulate GRB-2 expression followed by an assessment of
anti-CD28 induction of NF-B reporter activation. From this, it was
clear that the knock-down of GRB-2 in primary and Jurkat T-cells
blocked anti-CD28 mediated NF-B activation (Fig. 2d and e). The
efﬁciency of knock-down was conﬁrmed by western blotting of
total protein levels (insets) and quantiﬁed relative to endogenous
116 Y.R. Thaker et al. / Immunology Letters 163 (2015) 113–119
Fig. 2. GRB-2 connects proximal signals to regulate CD28 driven NF-B pathway. (a) Cd28−/− cells were reconstituted with empty vector, WT CD28 or N193Q mutant. FACS
histogram shows surface expression of WT or N193Q CD28 by staining with FITC labeled antibodies to CD28. Right panel shows another representative experiment obtained
from  CH7C17, CD28 deﬁcient cell line. NF-B luciferase activity was measured after stimulation with indicated antibodies. (b) Y170F knock-in mutant primary T-cells were
used  in conjunction with wild type primary cells. Luciferase ﬁreﬂy units were normalized to background Renilla values. (c) Binding of Grb-2 to CD28. Jurkat T-cells, either
left  unstimulated (lane 2) or stimulated with anti-CD28/rabbit anti-mouse IgG for 1, 5, 15 and 30 min  (lanes 3–6) were lysed, immunoprecipitated with anti-CD28 and
blotted  for Grb-2. Immunoprecipitation with rabbit anti-mouse IgG served as a negative control (lane 1). Input panels: blotting of cell lysates with Grb-2 (upper panel) or
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o  endogenous actin levels (inset column chart). All siRNA were purchased from Dh
ctin levels by densitometric analysis. The use of primary and Jurkat
-cells showed that anti-CD28 activation of NF-B required GRB-2
xpression and its binding to CD28.
.3. The adaptor ADAP is not needed for direct CD28 activation of
F-B
Previous reports have shown a role of ADAP-CARMA1-Bcl10-
alt1 complex in the regulation of NF-B in T-cells in response
o co-ligation by TCR/CD28 [47–49]. However, the role of ADAP in
nti-CD28 stimulation alone of NF-B had not been examined. To
ssess this, we next examined the effects of anti-CD28 on primary
-cells from adap−/− mice (Fig. 3a). Anti-CD28 induced the normal
- to 4-fold increase in reporter activity in adap−/− T-cells. Further,
ransfection of the cells with ADAP failed to increase this further,
nd occasionally even reduced NF-B activity. In contrast, anti-CD3
F-B activation was impaired in adap−/− cells as compared to wild
ype cells which showed normal NF-B activation. As a control, cells (d) and Jurkat cells (e) and its effects on NF-B pathway after 48 and 72 h of
hown in insets (SC: scrambled and KD: knock-down) and quantiﬁed by normalizing
on (Thermo Scientiﬁc).
the reconstitution of primary cells with exogenous ADAP restored
normal or higher levels of NF-B activation in response to anti-
CD3. Levels of over-expressed ADAP in reconstituted cells were
comparable to endogenous ADAP levels expressed by wild type
cells (inset). No substantial differences in CD28 expression were
observed on adap−/− cells as measured by total CD28 blot (inset).
Similarly, anti-CD28 was used to activate NF-B reporter activity in
vector or CD28 expressing Jurkat 1G4 cells transfected with ADAP
or SKAP1 (Fig. 3b). ADAP binds to SKAP1 in a pathway linked to the
activation of integrin adhesion [50,51]. Again, the over-expression
of neither ADAP nor SKAP1 enhanced anti-CD28 induced NF-B
activity, and occasionally, we  even observed an inhibition of activ-
ity. Immune blotting conﬁrmed expression of transfected proteins
in cells (right insets).In another approach, we also examined whether ADAP expres-
sion could potentiate anti-CD3 or anti-CD28 activation of NF-B
in LAT deﬁcient Jcam2 T-cells (Fig. 3c). LAT is an adaptor that
operates upstream of ADAP in the anti-CD3 activation cascade
Y.R. Thaker et al. / Immunology Letters 163 (2015) 113–119 117
Fig. 3. Normal CD28 but defective TCR mediated NF-B pathway in ADAP KO primary and LAT deﬁcient Jurkat cells. (a) CD3+ cells isolated from spleens of adap−/− (silver bars)
or  wild type (blue bars) mice were used for NF-B IL-2 promoter assay by transfecting with reporter plasmids followed by stimulation with control, anti-CD28 or anti-CD3
antibodies. Right panel, NF-B activity in adap−/− (blue bars) compared to controls wild type (silver bars) or adap−/− T-cells transfected with exogenous ADAP (green bars).
Efﬁciency of transfection was assessed by western blotting and normalized to endogenous CD28 levels as shown by column chart (inset). Each point is average of triplicate
with  SD. (b) NF-B activity measured in CD28 reconstituted Jurkat 1G4 cells transfected with adapters SKAP1 or ADAP (Fyb) or control plasmids as shown. NF-B activity
was  measured as above. (c) NF-B reporter activity in LAT deﬁcient (Jcam2) cells, either transfected with VAV1 (green bars) or ADAP (silver bars) when engaged with control
(RaM),  anti-CD28 or anti-CD3 antibodies. Wild type (Jurkat) transfected with respective plasmids were used as control. All values are relative luciferase units and average
of  triplicates with standard deviations. (d) Reconstitution of Cd28−/− Jurkat cells with VAV1 or respective controls. NF-B activation in response to CD28 was measured as
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ctin  normalized values in column chart (inset). (For interpretation of the reference
n a number of contexts [2,52–54]. Interestingly, anti-CD28 could
eadily activate NF-B in the absence of LAT expression. By con-
rast, anti-CD3 was completely impaired in the activation of NF-B
eporter activity in LAT deﬁcient cells, but not wild type cells, as was
ts further enhancement by the transfection with ADAP (Fig. 3a, c).
his observation underscored the fundamental differences in the
D28 and TCR regulation of NF-B, indicating that anti-CD3 medi-
tion of NF-B activation but not CD28 was dependent on the LAT
daptor.
Given the lack of a connection between CD28 and ADAP, we
ext assessed whether another adaptor may  play a role in medi-
ting CD28 effects. We  previously showed that GRB-2 binding to
D28 involved the additional binding to the GEF VAV1 [37,38].
uosto et al. have reported that VAV1 can cooperate with CD28
o induce NF-B activation via a pathway involving Rac-1 and
itogen-activated kinase kinase 1 [31,41]. In agreement, trans-
ection of Jurkat cells with VAV1 resulted repeatedly in a major
ncrease in NF-B promoter activation (i.e. 4-fold increase) asured from reporter plasmids when cells were stimulated for 6 h with control (RH),
ng of endogenous proteins and quantiﬁed by densitometric analysis and shown as
olor in this ﬁgure legend, the reader is referred to the web version of this article.)
compared to vector-transfected cells (Fig. 3d). VAV1 expression
by transfection was conﬁrmed by immune blotting (inset) and
surface expression of CD28 expressing clones was  analyzed by FACS
(inset FACS histogram). Further, the siRNA knock-down of VAV1
expression (see inset) impaired the ability of anti-CD28 to increase
NF-B activity (Fig. 3e). As quantiﬁed, siRNA depleted about 60%
of endogenous protein (inset graph). By contrast, only minor effect
was seen on anti-CD3 mediated NF-B activation. Further, we also
observed that the ability of VAV1 transfection to cooperate with
anti-CD28 could be seen in LAT deﬁcient Jcam2 cells (Fig. 3c). Over-
all, this observation showed that CD28 co-operated with VAV1 to
augment NF-B activity and this operated independently of the LAT
adaptor.4. Discussion
Overall, our ﬁndings show that CD28 and the TCR complex
engaged distinct signaling modules, GRB-2/VAV1 and LAT/ADAP
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espectively, in the activation of NF-B. These observations
ould have important implications for our understanding of the
ntracellular signaling mechanisms that control T-cell function, and
nderscore the independent nature of signaling by CD28. CD28
an enhance signaling via the antigen-receptor [55], but also has
he capacity to complement the TCR complex by engaging an
ndependent pathway for the convergent activation of NF-B. Pre-
ious studies have reported the importance of both TCR and CD28
eceptors in the activation of NF-B [56,57]. However, despite this
ccumulating evidence showing CD28 independent signaling in T-
ells, most previous studies have examined responses mostly in
urkat cells. The potential deﬁnition of distinct pathways in pri-
ary T-cells had been missing. Importantly, recent studies have
mplicated the adaptor ADAP (alias FYB, SLAP-130) in the acti-
ation of NF-B in response to anti-CD3/CD28 co-ligation. It has
een unclear whether independent CD28 signaling also requires or
ses the ADAP pathway. Using adap−/− primary T-cells, we found
hat anti-CD28 could activate NF-B without the expression of
DAP. This contrasted with the TCR complex where NF-B acti-
ation was markedly impaired in the absence of ADAP. Further,
n a complementary approach, while the over-expression of ADAP
ubstantially increased anti-CD3 mediated of NF-B reporter activ-
ty, the over-expression of ADAP, or its binding partner SKAP1 (alias
KAP-55) had little if any effect in anti-CD28 driven activation. Con-
istent with this theme, while anti-CD3 activation of NF-B was
arkedly impaired in LAT deﬁcient Jcam2 cells, anti-CD28 readily
ctivated NF-B in these T-cells. This observation was in keeping
ith the close connection between the TCR and LAT in the activa-
ion of T-cells [2]. It is also consistent with the notion that the LAT
ignalosome is comprised of a complex that binds to SLP-76 and
hich in turn binds via its SH2 domain to ADAP [1,53,58].
Overall, while the TCR pathway depends on LAT and associated
DAP to activate the NF-B pathway, our data show that CD28
ses a distinct pathway that does not depend on this pathway.
nstead, we found that GRB-2 and VAV1 are key elements in the
D28 pathway. We  have previously shown that GRB-2 can bind
ia two domains to CD28. Further, we have shown that GRB-2
an bind to VAV1 when associated with CD28 [38]. In particu-
ar, CD28 and GRB-2, relative to Gads or Grap, can preferentially
ooperate with VAV1 in the activation of NFAT/AP-1 transcrip-
ion [38]. Given the previous ﬁnding that the loss of GADS or
RB-2 was needed for CD28 activation of NF-B in Jurkat cells
39], we reassessed the binding of GADS and GRB-2, and found
hat only GRB-2 reproducibly bound to CD28. Further, the loss
f the N residue in the YMNM motif in Jurkat cells, or the Y in
rimary T-cells abrogated anti-CD28 induction of NF-B activa-
ion. We  also showed that anti-CD28 cooperated with VAV1 as
eported by others [31]. Further, the knock-down of GRB-2 by siRNA
arkedly impaired NF-B activation in primary and Jurkat cells in
esponse to anti-CD28. Combined with our previous demonstration
hat GRB-2 can bind to VAV1 [34], these ﬁndings are consistent
ith a model where CD28 can employ GRB-2 to engage VAV1 in
he activation of NF-B. CD28 could use the YMNM/GRB-2 as an
nitiation switch to regulate VAV1/SLP-76 module toward NF-B
ctivation.
Overall, these ﬁndings highlighted the distinct requirements for
he TCR and CD28 in the activation of NF-B pathway. It seems a
easonable assumption that TCR and CD28 would engage distinct
ediators that in turn complement each other for the full activa-
ion of NF-B transcription in T-cells. This might also provide a
echanistic explanation for the partial defects in NF-B activation
hat have been observed in CD28 and ADAP KO mice. The distinct
pstream mediators may  also induce distinct down-stream com-
lexes as in previous report showing that CD28 ligation induces
omplexes of Bcl10-PKC [59] that are distinct from CBM-ADAP
omplex of TCR pathway [29].
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